T-Cell Receptor Vα Usage by Effector CD4+Vβ11+ T Cells Mediating Graft-versus-Host Disease Directed to Minor Histocompatibility Antigens Christine G.

Slides:

Advertisements

Similar presentations

Induction of Graft-versus-Leukemia (GVL) Effect without Graft-versus-Host Disease (GVHD) by Pretransplant Donor Treatment with Immunomodulators Shoshana.

Advertisements

Quantitative Detection and Differentiation of Human Herpesvirus 6 Subtypes in Bone Marrow Transplant Patients by Using a Single Real-Time Polymerase Chain.

Joseph H. Chewning, Weiwei Zhang, David A. Randolph, C

Reduced Graft-versus-Host Disease in C3-Deficient Mice Is Associated with Decreased Donor Th1/Th17 Differentiation Qing Ma, Dan Li, Roza Nurieva, Rebecca.

Host-Derived CD8+ Dendritic Cells Protect Against Acute Graft-versus-Host Disease after Experimental Allogeneic Bone Marrow Transplantation Michael Weber,

Depletion of Naïve Lymphocytes with Fas Ligand Ex Vivo Prevents Graft-versus-Host Disease without Impairing T Cell Support of Engraftment or Graft-versus-Tumor.

The Fifth Epidermal Growth Factor–like Region of Thrombomodulin Alleviates Murine Graft-versus-Host Disease in a G-Protein Coupled Receptor 15 Dependent.

Secondary Lymphoid Organs Contribute to, but Are Not Required for the Induction of Graft-versus-Host Responses following Allogeneic Bone Marrow Transplantation:

Expression of Chemokines in GVHD Target Organs Is Influenced by Conditioning and Genetic Factors and Amplified by GVHR Markus Y. Mapara, Corinna Leng,

Influence of Donor Microbiota on the Severity of Experimental Graft-versus-Host- Disease Isao Tawara, Chen Liu, Hiroya Tamaki, Tomomi Toubai, Yaping Sun,

Host-Derived Interleukin-18 Differentially Impacts Regulatory and Conventional T Cell Expansion During Acute Graft-Versus-Host Disease Robert Zeiser,

IL-2–Targeted Therapy Ameliorates the Severity of Graft-versus-Host Disease: Ex Vivo Selective Depletion of Host-Reactive T Cells and In Vivo Therapy

A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation.

Identification of Stem Cell Transcriptional Programs Normally Expressed in Embryonic and Neural Stem Cells in Alloreactive CD8+ T Cells Mediating Graft-versus-Host.

Juyang Kim, Wongyoung Kim, Hyun J. Kim, Sohye Park, Hyun-A

Differential Effects of Gut-Homing Molecules CC Chemokine Receptor 9 and Integrin-β7 during Acute Graft-versus-Host Disease of the Liver Alina Schreder,

Induction of Immunity to Neuroblastoma Early after Syngeneic Hematopoietic Stem Cell Transplantation Using a Novel Mouse Tumor Vaccine Weiqing Jing,

Adoptive Immunotherapy Against Allogeneic Kidney Grafts in Dogs with Stable Hematopoietic Trichimerism Scott S. Graves, William J. Hogan, Christian Kuhr,

Ping Zhang, Jieying Wu, Divino Deoliveira, Nelson J. Chao, Benny J

Volume 128, Issue 7, Pages (June 2005)

LBH589 Enhances T Cell Activation In Vivo and Accelerates Graft-versus-Host Disease in Mice Dapeng Wang, Cristina Iclozan, Chen Liu, Changqing Xia, Claudio.

Inhibition of the Immunoproteasome Subunit LMP7 with ONX 0914 Ameliorates Graft- versus-Host Disease in an MHC-Matched Minor Histocompatibility Antigen–Disparate.

A Role for TNF Receptor Type II in Leukocyte Infiltration into the Lung during Experimental Idiopathic Pneumonia Syndrome Gerhard C. Hildebrandt, Krystyna.

Preactivation with IL-12, IL-15, and IL-18 Induces CD25 and a Functional High-Affinity IL-2 Receptor on Human Cytokine-Induced Memory-like Natural Killer.

Immune Tolerance to Self-Major Histocompatability Complex Class II Antigens after Bone Marrow Transplantation: Role of Regulatory T Cells Allan D. Hess,

PreImplantation Factor Reduces Graft-versus-Host Disease by Regulating Immune Response and Lowering Oxidative Stress (Murine Model) Yehudith Azar, Reut.

Blocking LFA-1 Activation with Lovastatin Prevents Graft-versus-Host Disease in Mouse Bone Marrow Transplantation Yang Wang, Dan Li, Dan Jones, Roland.

Volume 116, Issue 3, Pages (March 1999)

IL-17 Gene Ablation Does Not Impact Treg-Mediated Suppression of Graft-Versus-Host Disease after Bone Marrow Transplantation Lucrezia Colonna, Mareike.

Volume 44, Issue 6, Pages (June 2006)

Induction of Graft-versus-Leukemia (GVL) Effect without Graft-versus-Host Disease (GVHD) by Pretransplant Donor Treatment with Immunomodulators Shoshana.

The Synthetic Triterpenoid, CDDO, Suppresses Alloreactive T Cell Responses and Reduces Murine Early Acute Graft-versus-Host Disease Mortality Kai Sun,

Therapeutic Effects of a NEDD8-Activating Enzyme Inhibitor, Pevonedistat, on Sclerodermatous Graft-versus-Host Disease in Mice Chien-Chun Steven Pai,

Evelyn C. Nieves, Tomomi Toubai, Daniel C

Treatment with a Rho Kinase Inhibitor Improves Survival from Graft-Versus-Host Disease in Mice after MHC-Haploidentical Hematopoietic Cell Transplantation

Graft-versus-Host Disease–Related Cytokine-Driven Apoptosis Depends on p73 in Cytokeratin 15–Positive Target Cells Qian Zhan, Robert Korngold, Cecilia.

The Triterpenoid CDDO-Me Delays Murine Acute Graft-versus-Host Disease with the Preservation of Graft-versus-Tumor Effects after Allogeneic Bone Marrow.

Inhibition of Cathepsin S Reduces Allogeneic T Cell Priming but Not Graft-versus-Host Disease Against Minor Histocompatibility Antigens Hisaki Fujii,

Genital Chronic Graft-versus-Host Disease in Females: A Cross-Sectional Study Eva Smith Knutsson, Yvonne Björk, Anna-Karin Broman, Lotti Helström, Anne-Marie.

Sequential Expression of Adhesion and Costimulatory Molecules in Graft-versus-Host Disease Target Organs after Murine Bone Marrow Transplantation across.

George F Murphy, Robert Korngold

An Essential Role for IFN-γ in Regulation of Alloreactive CD8 T Cells Following Allogeneic Hematopoietic Cell Transplantation Wannee Asavaroengchai,

Survival and Function of MiHA Epitope-Specific Host CD8 TM Cells Following Ablative Conditioning and HCT Alwi M. Shatry, Derry C. Roopenian, Robert B.

Therapeutic Benefit of Bortezomib on Acute Graft-versus-Host Disease Is Tissue Specific and Is Associated with Interleukin-6 Levels Chien-Chun Steven.

Lisa A. Palmer, George E. Sale, John I

Differential Expression of the Ly49GB6, but Not the Ly49GBALB, Receptor Isoform during Natural Killer Cell Reconstitution after Hematopoietic Stem Cell.

Murine Bone Marrow Stromal Progenitor Cells Elicit an In Vivo Cellular and Humoral Alloimmune Response Andrea T. Badillo, Kirstin J. Beggs, Elisabeth.

Reciprocal Expression of Enteric Antimicrobial Proteins in Intestinal Graft-Versus-Host Disease Yoshihiro Eriguchi, Hidetaka Uryu, Kiminori Nakamura,

The Triterpenoid CDDO-Me Delays Murine Acute Graft-versus-Host Disease with the Preservation of Graft-versus-Tumor Effects after Allogeneic Bone Marrow.

Effector Cells Derived from Host CD8 Memory T Cells Mediate Rapid Resistance against Minor Histocompatibility Antigen-Mismatched Allogeneic Marrow Grafts.

A Radio-Resistant Perforin-Expressing Lymphoid Population Controls Allogeneic T Cell Engraftment, Activation, and Onset of Graft-versus-Host Disease in.

Mammalian Target of Rapamycin Inhibitors Permit Regulatory T Cell Reconstitution and Inhibit Experimental Chronic Graft-versus-Host Disease Haruko Sugiyama,

A CD4 Domain 1 CC′ Loop Peptide Analogue Enhances Engraftment in a Murine Model of Bone Marrow Transplantation with Sublethal Conditioning Gabor Varadi,

In Situ Activation and Expansion of Host Tregs: A New Approach to Enhance Donor Chimerism and Stable Engraftment in Major Histocompatibility Complex-Matched.

Treatment with GM-CSF Secreting Myeloid Leukemia Cell Vaccine Prior to Autologous- BMT Improves the Survival of Leukemia-Challenged Mice Jenny Zilberberg,

Recipient B Cells Are Not Required for Graft-Versus-Host Disease Induction Catherine Matte-Martone, Xiajian Wang, Britt Anderson, Dhanpat Jain, Anthony.

Interleukin 17 Is Not Required for Autoimmune-Mediated Pathologic Damage during Chronic Graft-versus-Host Disease Xiao Chen, Rupali Das, Richard Komorowski,

The Innate Immune Sensor Sting Can Augment or Ameliorate Graft-Versus-Host Disease Dependent on the Genetic Disparity between Donors and Recipients Cameron.

CD25 expression distinguishes functionally distinct alloreactive CD4+ CD134+ (OX40+) T-cell subsets in acute graft-versus-host disease Philip R Streeter,

Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD4+25+ T cells to allow an effective graft-versus-leukemia response

Brile Chung, Eric Dudl, Akira Toyama, Lora Barsky, Kenneth I. Weinberg

T-Cell Receptor Vα Spectratype Analysis of a CD4-Mediated T-Cell Response against Minor Histocompatibility Antigens Involved in Severe Graft-versus-Host.

Specific donor Vβ-associated CD4+ T-cell responses correlate with severe acute graft- versus-host disease directed to multiple minor histocompatibility.

Volume 131, Issue 2, Pages (August 2006)

CD8 T-cell ability to exert immunodomination correlates with T-cell receptor: Epitope association rate Guillaume Roy-Proulx, Chantal Baron, Claude Perreault

An epithelial target site in experimental graft-versus-host disease and cytokine-mediated cytotoxicity is defined by cytokeratin 15 expression Diana.

Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution Maria Gendelman, Maryam Yassai,

Induction of Lethal Graft-versus-Host Disease by Anti-CD137 Monoclonal Antibody in Mice Prone to Chronic Graft-versus-Host Disease Wonyoung Kim, Juyang.

Roles of CD28, CTLA4, and Inducible Costimulator in Acute Graft-versus-Host Disease in Mice Jun Li, Kenrick Semple, Woong-Kyung Suh, Chen Liu, Fangping.

Volume 23, Issue 4, Pages (October 2005)

Presentation transcript:

T-Cell Receptor Vα Usage by Effector CD4+Vβ11+ T Cells Mediating Graft-versus-Host Disease Directed to Minor Histocompatibility Antigens Christine G. DiRienzo, George F. Murphy, Thea M. Friedman, Robert Korngold Biology of Blood and Marrow Transplantation Volume 13, Issue 3, Pages 265-276 (March 2007) DOI: 10.1016/j.bbmt.2006.11.012 Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Evolution of B6→BALB.B GVHD in lingual epithelium, days 10 and 15. (A) On day 10, hematoxylin and eosin histology reveals lymphocytes within the superficial submucosa and epithelium. The small, somewhat hyperchromatic lymphocyte nuclei can be easily differentiated from the larger, more open nuclei of the squamous mucosal or columnar epithelial target cells they are infiltrating. (B) The lymphocytes increase in number by day 15, when they become more concentrated at the rete-like ridges and associated with target cell apoptosis (arrow; inset is B6→B6 d15 control). (C, D) Immunohistochemistry demonstrates that > 90% of these lymphocytes express Vβ11. Note the tendency of these cells to associate with target cells in the basal layer by day 15 [arrow in (D); the inset represents negative staining for Vβ5 in adjacent section]. (E, F) The B6→B6 control tongue failed to show Vβ11 infiltration at day 10 (E) and day 15 (F). Biology of Blood and Marrow Transplantation 2007 13, 265-276DOI: (10.1016/j.bbmt.2006.11.012) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Evolution of B6→BALB.B GVHD in intestinal epithelium, days 10 and 15. Pathological changes are not apparent at day 10 (A) but are noted by day 15 (B), consisting of lymphoid infiltration and apoptosis of crypt epithelium (arrows). The inset in (B) depicts day 15 B6→B6 control. (C) Rare Vβ11+ cells are present at day 10 (arrow), whereas numerous positive cells are present at day 15 (D). In (D), the inset is staining for Vβ5 in an adjacent section. The B6→B6 control gut fails to show significant infiltration by Vβ11-positive cells at either day 10 (E) or day 15 (F). Biology of Blood and Marrow Transplantation 2007 13, 265-276DOI: (10.1016/j.bbmt.2006.11.012) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Isolation of responding B6 CD4+Vβ11+ T cells. B6 mice were serially immunized with BALB.B splenocytes (2 × 107, IP) on days 0, 17, and 42. On day 63, spleen and LN CD4+ T cells from these mice were labeled with CFSE and cultured for 3 days with either L-mimosin to distinguish nondividing cells (A) or irradiated BALB.B splenocytes that were depleted of all T cells (B). Histograms, gated on CFSE+CD4+Vβ11+ T cells, indicated that most of the allostimulated cells underwent division, marked by decreased CFSE intensity. Biology of Blood and Marrow Transplantation 2007 13, 265-276DOI: (10.1016/j.bbmt.2006.11.012) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Alignment of TRAV sequences isolated from CFSE-labeled B6 CD4+Vβ11+ T cells. After RNA extraction from CFSElow-negative CD4+Vβ11+ T cells, cDNA was enriched for TCRα chain transcripts using a NotI-Cα3 primer and subsequently amplified using NPA-PCR. Products were visualized on an agarose gel, gel-purified, then cloned into a pGEM T-Easy vector. DNA sequences isolated from bacteria colonies and sequences were aligned for similarity using the CLUSTALW program. All sequences were compared to those found in the IMGT database using the IMGT/V-QUEST program. (A) Sequence alignment of all sequences, in frame and out of frame. All sequences were compared against CD-D16, which was used as a reference sequence for comparison with the other sequences for similarity or differences. Dashes represent nucleotide identity, and dots represent nucleotide gaps. Nucleotides that differ from the reference sequence have the letters written in the areas that differ. CD-D16, CD-D14, CD-D2, CD-D6, and CD-D10 contain the sequences for TRAV13-TRAJ16. CD-D12, CD-D37 CD-D1, CD-D3, and CD-D4 contain the sequences with TRAJ17. CD-D9 contains an out-of-frame sequence for TRAV13–TRAJ43. CD-D13 is an incomplete sequence and contains only TRAJ and TRAC regions. (B) TRAV13–TRAJ16. Note that the amino acids are included above the nucleotide sequences in the alignment. TRAV, N (N-region additions), TRAJ, and TRAC regions are indicated above nucleotides. Biology of Blood and Marrow Transplantation 2007 13, 265-276DOI: (10.1016/j.bbmt.2006.11.012) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 5 LMD targeting of B6 Vβ11+ T cells in BALB.B organs. B6 CD4+ T cells (2 × 107) and ATBM (2 × 106) were transferred into lethally irradiated (10 Gy) BALB.B or control B6 recipients. Immunohistochemistry of uncoverslipped tissue sections stained with Vβ11 antibody and counterstained with hematoxylin. (A, B) LMD-targeted areas of lingual epithelium RLP before (A) and after (B) LMD. (C, D) Targeted areas of small intestines before (C) and after (D) LMD. Control mice were lethally irradiated (10 Gy) and injected with 2 × 106 B6 ATBM. (E, F) RLP of control mice before (E) and after (F) LMD. (G, H) Targeted intestinal areas of control mice before (G) and after (H) LMD. Note the areas that have been extracted by LMD. The pictures are from 1 mouse and are representative of 2 separate experiments, each with n = 3. Biology of Blood and Marrow Transplantation 2007 13, 265-276DOI: (10.1016/j.bbmt.2006.11.012) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 6 PCR amplification of TRAV isolated by LMD. Amplified products were visualized on 3% agarose gels. CD4 (285bp) and TRAV13–TRAJ16 (69 bp)-specific primers were used to amplify DNA from LMD-extracted lingual (A and C) and intestinal epithelium (B and D) 15 days after transplantation of either 2 × 107 B6 CD4+ T cells and 2 × 106 ATBM into BALB.B recipients (10 Gy) (A and B) or 2 × 106 B6 ATBM into B6 recipients (10 Gy) (C and D). For each gel, lane 1 is a 100-bp ladder, and lanes 2-4 are each amplified products from a single mouse and are representative of 2 separate experiments (n = 6). Biology of Blood and Marrow Transplantation 2007 13, 265-276DOI: (10.1016/j.bbmt.2006.11.012) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions